[1] Silverman JA, Deitcher SR. Marqibo (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine[J]. Cancer Chemother Pharmacol, 2013, 71(3): 555-564.
[2] Dennison JB, Jones DR, Renbarger JL, et al. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes[J]. J Pharmacol Exp Ther, 2007, 321(2): 553-563.
[3] Dennison JB, Mohutsky MA, Barbuch RJ, et al. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes[J]. J Pharmacol Exp Ther, 2008, 327(1): 248-257.
[4] van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy[J]. Drug Resistance Updates, 2008, 11(3): 77-98.
[5] Lange BJ, Bostrom BC, Cherlow JM, et al. Doubledelayedintensi fication improves eventfree survival for children with intermediaterisk acute lymphoblastic leukemia: a report from the Children′s Cancer Group[J]. Blood, 2002, 99(3): 825-833.
[6] Egbelakin A, Ferguson MJ, MacGill EA, Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2011, 56(3): 361-367.
[7] Brūggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents[J]. Clin Infect Dis, 2009, 48(10): 1441-1458.
[8] 冷玲, 佟仲生. 常用化疗药物的脂质体剂型[J]. 国际肿瘤学杂志, 2008, 35(8): 585-587.
[9] 李文静, 杨志强, 王杏林. 硫酸长春新碱脂质体研究进展[J]. 中国新药杂志, 2012, 21(13): 1479-1484. |